http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101692378-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d1750b578ca9a780678f6b9b9c8b87d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2016-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd01bef5b284b6262a11a1249c018028 |
| publicationDate | 2017-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101692378-B1 |
| titleOfInvention | Novel Use of Sesquiterpene Derivatives |
| abstract | The present invention relates to a novel use of a sesquiterpene derivative, and more particularly to a novel use of a sesquiterpene derivative compound represented by the formula (1) of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient, To a composition for the prevention, amelioration or treatment of macular degeneration or macular edema due to vascular leakage. In contrast to the inconvenience that the commercially available intraocular disease-related therapeutic agents must be directly administered into the vitreous cavity, and pain and side effects thereof, the sesquiterpene derivative compound of the present invention is administered by other routes other than intravenous administration (oral administration, (Intraperitoneal injection, etc.), and the effect is excellent because it has a therapeutic effect regardless of the route of administration. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180138109-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3482750-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10918625-B2 |
| priorityDate | 2016-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 109.